Lucid Diagnostics Inc. (LUCD) Income Statement
LUCD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLUCD revenue and net income
Where LUCD's revenue goes
2025Each bar shows an amount and its share of revenue. LUCD kept −1,232.7% of revenue as net income.
LUCD profit margins
LUCD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +8.3% | +132.0% | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LUCD quarterly EPS vs estimates
Lucid Diagnostics beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.05).
LUCD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377,000 | $500,000 | $0 | $0 | $0 |
| Cost of revenue | $7.5M | $8.3M | $8.5M | $3.6M | $585,000 | $0 | — | — |
| Gross profit | −$2.8M | −$3.9M | −$6.0M | −$3.2M | −$85,000 | $0 | — | — |
| Research & development | $5.68B | $6.0M | $7.3M | $11.5M | $9.3M | $5.4M | $3.5M | $715,629 |
| Sales, general & admin | $23.87B | $20.16B | $35.7M | $39.8M | $18.0M | $2.8M | $958,722 | $615,428 |
| Total operating expenses | $46.8M | $42.1M | $42.4M | $52.9M | $27.3M | $8.3M | $4.4M | $1.1M |
| Operating income | −$49.6M | −$46.1M | −$48.5M | −$56.2M | −$27.4M | −$8.3M | −$4.4M | −$1.1M |
| Interest income | $386,000 | $322,000 | $424,000 | $88,000 | — | — | — | — |
| Interest expense | $22,000 | $26,000 | $416,000 | $8,000 | $659,000 | $0 | $0 | $0 |
| Income before taxes | −$58.0M | −$45.5M | −$52.7M | −$56.2M | −$28.1M | −$8.3M | −$4.4M | −$1.1M |
| Income taxes | $12.56B | $7.50B | $2.3M | $1.7M | $659,000 | −$8.3M | −$4.4M | −$1.7M |
| Net income | −$58.0M | −$45.5M | −$52.7M | −$56.2M | −$28.1M | −$8.3M | −$4.4M | −$1.1M |
| EBITDA | −$57.1M | −$44.3M | −$49.8M | −$54.2M | −$27.4M | −$8.3M | −$4.4M | $562,957 |
| EPS (diluted) | −$0.46 | −$0.99 | −$0.92 | −$1.02 | −$1.82 | −$0.97 | −$0.33 | −$0.03 |
| Gross margin | −60.3% | −90.2% | −249.2% | −858.6% | −17.0% | — | — | — |
| Operating margin | −1,054.8% | −1,059.6% | −1,996.8% | −14,899.5% | −5,483.8% | — | — | — |
| Net margin | −1,232.7% | −1,047.6% | −2,169.1% | −14,899.5% | −5,615.6% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.3M | $1.5M | $1.2M | $1.2M | $828,000 | $1.2M | $1.2M | $976,000 | $1.0M | $1.0M | $783,000 |
| Cost of revenue | $1.4M | $1.8M | $1.9M | $1.7M | $1.8M | $1.6M | $2.1M | $1.7M | $1.6M | $1.7M | $1.5M | $1.6M |
| Gross profit | $29,000 | −$591,000 | −$356,000 | −$486,000 | −$622,000 | −$723,000 | −$948,000 | −$512,000 | −$638,000 | −$655,000 | −$417,000 | −$851,000 |
| Research & development | $1.2M | $1.2M | $1.7M | $1.3M | $1.3M | $1.4M | $1.5M | $1.7M | $1.4M | $1.5M | $1.9M | $1.6M |
| Sales, general & admin | $11.5M | $5.43B | $11.8M | $9.9M | $5.62B | $10.2M | $9.9M | $9.4M | $9.1M | $8.3M | $8.6M | $8.2M |
| Total operating expenses | $12.8M | $11.5M | $13.7M | $11.3M | $10.8M | $11.8M | $11.4M | $11.2M | $10.6M | $10.1M | $11.0M | $10.3M |
| Operating income | −$12.8M | −$12.1M | −$14.0M | −$11.8M | −$11.4M | −$12.5M | −$12.4M | −$11.7M | −$11.2M | −$10.8M | −$11.5M | −$11.1M |
| Interest income | $77,000 | $70,000 | $110,000 | $101,000 | $110,000 | $66,000 | $66,000 | $81,000 | $107,000 | $68,000 | $94,000 | $116,000 |
| Interest expense | $4,000 | $6,000 | $6,000 | $2,000 | $6,000 | $9,000 | $7,000 | $1,000 | $6,000 | $12,000 | $11,000 | $149,000 |
| Income before taxes | −$11.7M | −$13.9M | −$16.3M | −$10.4M | −$4.4M | −$26.9M | −$11.5M | −$12.4M | −$11.0M | −$10.6M | −$10.8M | −$14.2M |
| Income taxes | $3.03B | $9.72B | — | — | $3.45B | $9.11B | $7.50B | −$12.36B | — | $7.50B | −$1.96B | −$2.9M |
| Net income | −$11.7M | −$13.9M | −$16.3M | −$10.4M | −$4.4M | −$26.9M | −$11.5M | −$12.4M | −$11.0M | −$10.6M | −$10.8M | −$14.2M |
| EBITDA | −$11.5M | −$13.7M | −$16.1M | −$10.2M | −$4.2M | −$26.7M | −$11.3M | −$12.2M | −$10.8M | −$10.1M | −$10.2M | −$13.4M |
| EPS (diluted) | −$0.08 | −$0.07 | −$0.10 | −$0.10 | −$0.10 | −$0.16 | −$0.19 | −$0.20 | −$0.20 | −$0.40 | −$0.23 | −$0.22 |
| Gross margin | 2.0% | −47.1% | −23.7% | −40.1% | −53.5% | −87.3% | −79.2% | −43.7% | −65.4% | −65.4% | −40.1% | −108.7% |
| Operating margin | −868.5% | −964.5% | −931.6% | −971.0% | −978.8% | −1,508.1% | −1,033.8% | −997.8% | −1,146.7% | −1,078.1% | −1,101.2% | −1,421.2% |
| Net margin | −792.9% | −1,107.4% | −1,081.5% | −858.5% | −381.7% | −3,249.8% | −964.2% | −1,055.5% | −1,127.6% | −1,060.1% | −1,041.3% | −1,814.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LUCD's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LUCD financial results
In fiscal year 2025 (ended December 31, 2025), Lucid Diagnostics reported revenue of $4.7 million, up 8.3% from the year before. It had a net loss of $58.0 million, a net profit margin of −1,232.7%. Diluted earnings per share came to −$0.46.
See the LUCD stock overview for the latest quote and news, or the LUCD chart for price history and technical indicators.
LUCD income statement FAQ
What is Lucid Diagnostics's annual revenue?
Lucid Diagnostics reported total revenue of $4.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 8.3% from $4.3 million the previous year.
Is Lucid Diagnostics profitable?
No. Lucid Diagnostics reported a net loss of $58.0 million in fiscal 2025, a net profit margin of −1,232.7%; its operating margin was −1,054.8%.
What is Lucid Diagnostics's gross margin?
Lucid Diagnostics's gross margin was −60.3% in fiscal 2025: for every $100 of revenue, Lucid Diagnostics kept $-60 after the direct cost of its products and services.
How much does Lucid Diagnostics spend on research and development?
Lucid Diagnostics spent $5.7 billion on research and development in fiscal 2025, 120,654.5% of revenue.
What are Lucid Diagnostics's earnings per share?
Lucid Diagnostics earned $-0.46 per diluted share in fiscal 2025, compared with $-0.99 a year earlier.
When will Lucid Diagnostics report its next earnings?
Lucid Diagnostics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Lucid Diagnostics's fiscal year end?
Lucid Diagnostics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.